Author

Xiao-Yi Liu

h-index 0 View on Semantic Scholar

We have 2 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jan 2026

Regulatory‐Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys

Siltartoxatug—developed by Trinomab Pharmaceutical Co., Ltd., using its proprietary HitmAb® platform—is the first‐in‐class recombinant monoclonal antibody drug for urgent prophylaxis of tetanus approved by China National Medical Products Administration in February 2025, which addresses the critical unmet need to substi...

Xia Zhou, Fei Zhou, Zhen-Peng Fu et al. · Advances in pharmacological... · 0 citations

Open access Sep 2026

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection...

Xin-Yu Liu, Zhi-Gang Liu, Xiao-Hu Kuang et al. · Clinical pharmacology and th... · 0 citations